Core Viewpoint - Monopar Therapeutics Inc. reported a productive year in 2025, highlighted by advancements in its ALXN1840 program for Wilson disease, a strengthened balance sheet, and leadership team enhancements as it prepares for a potential drug launch [2] Recent Program Developments - ALXN1840 is set for a New Drug Application (NDA) submission in mid-2026, targeting Wilson disease, a rare genetic disorder that leads to copper accumulation in organs [3][4] - The drug operates through a novel mechanism as an albumin tripartite complex (ATC) activator, distinguishing it from existing therapies [3] - The MNPR-101 platform includes radiopharmaceutical programs targeting aggressive cancers, with ongoing Phase 1 clinical activities for MNPR-101-Zr and MNPR-101-Lu [4][6] Financial Highlights - Monopar's cash, cash equivalents, and short-term investments totaled $140.4 million as of December 31, 2025, expected to support operations through at least December 31, 2027 [8] - The net loss for Q4 2025 was $5.2 million ($0.61 per share), a decrease from $10.9 million ($2.23 per share) in Q4 2024 [9] - For the full year 2025, the net loss was $13.7 million ($1.85 per share), down from $15.6 million ($4.11 per share) in 2024 [9] Research and Development (R&D) Expenses - R&D expenses for Q4 2025 were $3.9 million, significantly lower than $9.9 million in Q4 2024, primarily due to the absence of one-time expenses from 2024 [10] - For the full year, R&D expenses were $9.9 million, down from $13.0 million in 2024, reflecting a shift in focus following the in-licensing of ALXN1840 [11] General and Administrative (G&A) Expenses - G&A expenses for Q4 2025 increased to $2.2 million from $1.2 million in Q4 2024, driven by higher personnel costs and legal fees [12] - For the year, G&A expenses rose to $6.8 million from $3.2 million in 2024, attributed to similar factors as the quarterly increase [13]

Core Insights - Monopar Therapeutics Inc. has appointed Susan Rodriguez as Chief Commercial and Strategy Officer to lead the company's commercial strategy and infrastructure as it prepares for the New Drug Application submission for ALXN1840, a therapy for Wilson disease, in the first half of 2026 [1][2] Company Overview - Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet medical needs, with a late-stage investigational therapy ALXN1840 for Wilson disease and several radiopharmaceutical programs [3] Leadership Appointment - Susan Rodriguez brings over 30 years of biopharmaceutical leadership experience, having previously served as Chief Operating Officer at Avadel Pharmaceuticals, where she contributed to a $2 billion acquisition [2] - Rodriguez has a proven track record in launching rare disease therapies and building commercial teams, which will be crucial for Monopar as it advances ALXN1840 toward approval [2] Product Development - ALXN1840 is positioned as the first major advancement in Wilson disease treatment in decades, with the company aiming to ensure broad patient access and maximize the therapy's impact [2]

Core Insights - Ocular Therapeutix is preparing to present topline results from the SOL-1 Phase 3 superiority trial for AXPAXLI™ in wet AMD at the 49 Macula Society Annual Meeting scheduled for February 25-28, 2026 [1][3] - The company plans to submit a New Drug Application (NDA) for AXPAXLI based on the SOL-1 52-week data, contingent on positive results and discussions with the FDA [1][3] - The SOL-R Phase 3 non-inferiority trial has completed randomization of 631 subjects, with topline results expected in Q1 2027 [1][3] - Ocular has a cash balance of $737.1 million as of December 31, 2025, which is projected to support operations into 2028 [1][5] Business Highlights - The SOL-1 trial is designed to evaluate the safety and efficacy of AXPAXLI in treating wet AMD, with a primary endpoint focused on maintaining visual acuity [3][16] - The SOL-R trial aims to demonstrate non-inferiority compared to aflibercept, with a primary endpoint at Week 56 [3][19] - The HELIOS-3 trial for diabetic retinopathy is currently underway, with a focus on subjects with moderately severe to severe non-proliferative diabetic retinopathy [4][24] Financial Performance - Total net revenue for Q4 2025 was $13.3 million, a decrease of 22.4% from $17.1 million in Q4 2024 [6] - For the full year 2025, total net revenue was $52.0 million, down 18.5% from $63.7 million in 2024 [6] - Research and development expenses increased to $50.8 million in Q4 2025 from $41.0 million in Q4 2024, reflecting ongoing clinical trial costs [7] - The company reported a net loss of $(64.7) million for Q4 2025, consistent with a net loss of $(48.4) million in Q4 2024 [10] Future Developments - The SOL-X open-label extension trial is expected to begin in Q2 2026, allowing subjects from SOL-1 and SOL-R to enroll for additional safety follow-up [3][21] - The company raised approximately $475 million from an equity offering in September 2025, with net proceeds supporting operations into 2028 [4]

Core Viewpoint - Aquestive Therapeutics, Inc. is facing significant challenges following the FDA's identification of deficiencies in its New Drug Application for Anaphylm, leading to a sharp decline in its stock price by approximately 40% [2]. Group 1: Company Overview - Aquestive Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for severe allergic reactions, including anaphylaxis [2]. Group 2: Regulatory Challenges - The FDA has identified deficiencies in the New Drug Application (NDA) for Anaphylm, which is a sublingual film intended for treating severe allergic reactions [2]. - These deficiencies currently prevent discussions regarding labeling and post-marketing requirements, raising concerns about the application's approvability ahead of the January 31, 2026, PDUFA action date [2]. Group 3: Market Reaction - Following the FDA's announcement, shares of Aquestive Therapeutics, Inc. experienced a significant intraday drop of approximately 40% [2].

Core Viewpoint - Axsome Therapeutics is on track to submit a New Drug Application (NDA) for AXS-12, a treatment for cataplexy in narcolepsy, by January 2026, following positive feedback from the FDA regarding the regulatory data package [2][3][4]. Company Overview - Axsome Therapeutics is a biopharmaceutical company focused on developing treatments for central nervous system (CNS) disorders, with a portfolio that includes FDA-approved therapies for major depressive disorder and excessive daytime sleepiness associated with narcolepsy [8]. Product Details - AXS-12 (reboxetine) is a selective norepinephrine reuptake inhibitor and cortical dopamine modulator, aimed at treating narcolepsy by promoting wakefulness and enhancing cognition [7]. - AXS-12 has received Orphan Drug Designation from the FDA, which may provide seven years of marketing exclusivity upon approval and a waiver of application user fees [5]. Clinical Development - The clinical development program for AXS-12 includes three controlled efficacy trials and a completed long-term safety trial, indicating a robust approach to validating the drug's effectiveness and safety [4]. Market Context - Narcolepsy is a serious neurological condition affecting the sleep-wake cycle, characterized by excessive daytime sleepiness and cataplexy, which impacts cognitive and social functioning and is associated with a higher mortality rate [6].

Core Insights - Nicox SA has successfully completed the generation and analysis of all key data required for New Drug Applications (NDAs) in the U.S. and China, including clinical trial and long-term stability data for the NCX 470 drug material and finished product [1][5][6] - The company is preparing for a pre-NDA meeting with the U.S. Food and Drug Administration (FDA) and plans to submit the NDA in the first half of 2026, with the Chinese submission expected shortly thereafter [5][6] Company Overview - Nicox SA is an international ophthalmology company focused on developing innovative solutions for vision maintenance and ocular health, with its lead product being NCX 470, a nitric oxide-donating eye drop for lowering intraocular pressure in glaucoma patients [4][7] - The company has licensing agreements for NCX 470 with Ocumension Therapeutics for the Chinese, Korean, and Southeast Asian markets, and with Kowa for the rest of the world [4][6] Future Milestones - The NDA submission for NCX 470 in the U.S. is on track for H1 2026, with the submission in China expected to follow shortly after [5][6] - A Phase 3 clinical program for NCX 470 has been initiated in Japan, managed and financed by Kowa [6]

Core Viewpoint - Monopar Therapeutics Inc. reported its third quarter 2025 financial results, highlighting advancements in its drug candidates and recent financing activities, indicating a strong position for future growth and regulatory submissions [1]. Recent Developments - ALXN1840 for Wilson Disease: New data presented at the 150th American Neurological Association Annual Meeting demonstrated long-term neurological efficacy and safety of ALXN1840, emphasizing its potential to positively impact both neurological and hepatic manifestations of Wilson disease [2][3]. - MNPR-101 for Radiopharmaceutical Use: The FDA cleared the IND application for MNPR-101-Lu, which aims to treat advanced or metastatic solid tumors, utilizing proprietary linker technology to enhance therapeutic efficacy [5]. Recent Financing Capital Raise and Share Repurchase - On September 23, 2025, Monopar priced a public offering of 1,034,433 shares at $67.67 per share, raising approximately $126.9 million in net proceeds [6]. - Following the offering, the company repurchased 550,229 shares from Tactic Pharma for $35 million, resulting in net proceeds of approximately $91.9 million after the share repurchase [7]. Financial Results for the Third Quarter Ended September 30, 2025 - Cash, cash equivalents, and investments totaled $143.7 million, sufficient to support operations through at least December 31, 2027, while advancing multiple clinical trials and R&D projects [9]. - The net loss for Q3 2025 was $3.4 million, or $0.48 per share, compared to a net loss of $1.3 million, or $0.37 per share, in Q3 2024 [10]. - R&D expenses increased to $2.59 million, primarily due to higher manufacturing activities and personnel costs [11]. - G&A expenses rose to $1.50 million, driven by increased board compensation and personnel expenses [12]. - Interest income increased by $556,129, attributed to higher bank balances and interest earned on U.S. Treasury securities [13]. Company Overview - Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet medical needs, with key programs including ALXN1840 for Wilson disease and various radiopharmaceutical candidates [14].

Summary of XORTX Therapeutics Webinar Company Overview - **Company**: XORTX Therapeutics (NasdaqCM:XRTX) - **Focus Areas**: Development of therapies for gout and autosomal dominant polycystic kidney disease (ADPKD) [9][12] Core Points and Arguments Gout Program - **Primary Focus**: Developing a formulation of oxypurinol for gout treatment, targeting allopurinol-intolerant patients [9][11] - **Market Opportunity**: Estimated at $700 million for allopurinol-intolerant gout patients, filling a gap left by febuxostat [11][15] - **Clinical Background**: The drug has a safe and effective clinical record established in over 800 patients [12] - **Regulatory Path**: Preparing to file a New Drug Application (NDA) within the next 12 to 14 months, with a review period of 9 to 12 months [19][26] - **Patient Demographics**: Approximately 50 million individuals have high uric acid levels, with 7 to 9 million diagnosed with gout [14] - **Pricing Strategy**: Projected launch price between $6,000 and $8,000 per patient per year [15] ADPKD Program - **Market Opportunity**: Estimated at $1 to $1.5 billion, with a focus on patients with high uric acid levels [12][24] - **Regulatory Path**: A single small registration trial may suffice for FDA approval [12] - **Current Treatment Landscape**: Tolvaptan is the only approved drug, costing $156,000 per patient per year, treating only 5% of patients [23][25] - **Potential Market Size**: Estimated peak net sales could exceed $1 billion by treating around 18,000 individuals [25] Development and Manufacturing - **Key Activities**: Preparing an Investigational New Drug (IND) application and conducting pharmacokinetic studies [10][20] - **Manufacturing Plans**: A year of stability testing is required before NDA filing [21][26] - **Team Expertise**: Strong developmental team with experience in drug development and commercialization [27][28] Additional Important Information - **Patent Protections**: Recent EU patent grants cover major countries, with U.S. patents extending through 2034 and additional layers through 2041 and 2043 [34][35] - **Commercialization Strategy**: Plans to establish manufacturing and distribution contracts in preparation for the product launch [36] - **Market Capitalization**: Currently around $4 million to $5 million, with potential for significant value creation as the NDA is submitted [38][39] Conclusion - **Investment Opportunity**: XORTX Therapeutics is positioned for growth with low-risk activities planned over the next 12 to 24 months, aiming to transition from a research-focused company to a revenue-generating entity [39]

Core Viewpoint - Biohaven's stock experienced a significant increase of over 6% following positive regulatory news from the FDA regarding its New Drug Application for troriluzole, outperforming the S&P 500 index's 1.5% gain on the same day [1]. Regulatory Progress - Biohaven disclosed in a filing with the SEC that the FDA informed the company that an advisory committee meeting for the New Drug Application (NDA) for troriluzole is no longer necessary [2]. - Troriluzole is aimed at treating spinocerebellar ataxia, a group of inherited neurological disorders affecting movement, and the drug's development faced initial setbacks, including the FDA's refusal to accept the filing [4]. Implications of Advisory Meeting Cancellation - The cancellation of the advisory meeting suggests that the FDA may have already made a decision regarding the NDA, although it does not guarantee a favorable outcome for Biohaven [5]. - Research indicates that approximately two-thirds of applications with canceled advisory meetings have received approval from the FDA since 2019, which explains the market's positive reaction to the news [6].

Financial Data and Key Metrics Changes - The company ended Q1 2025 with cash, cash equivalents, and investments of $343 million, up from $198.2 million as of December 31, 2024, indicating a strong improvement in liquidity [23] - R&D expenses for Q1 2025 were $37.9 million, compared to $30.8 million in Q1 2024, primarily due to increased preclinical and clinical costs [24] - G&A expenses increased to $6.6 million in Q1 2025 from $4.6 million in Q1 2024, driven by higher compensation and professional fees [24] - The net loss for Q1 2025 was $42.2 million, compared to $31.5 million in Q1 2024, reflecting increased expenses [25] Business Line Data and Key Metrics Changes - The pivotal trials for lorundrostat, including LAUNCH HTN and ADVANCE HTN, achieved statistically significant results in reducing systolic blood pressure in patients with uncontrolled hypertension [6][12] - The LAUNCH HTN trial demonstrated a placebo-adjusted reduction in systolic blood pressure of 9.1 mmHg at week six and maintained a reduction of 11.7 mmHg at week twelve [12][13] - The ADVANCE HTN trial showed a placebo-adjusted reduction of 7.9 mmHg in systolic blood pressure, confirming the efficacy of lorundrostat in a high-risk population [16][17] Market Data and Key Metrics Changes - A survey indicated that 95% of physicians are likely to prescribe lorundrostat if approved, particularly in third and fourth-line treatment positions for hypertension [8] - The company is targeting a significant market opportunity, with over 20 million patients in the US suffering from uncontrolled and resistant hypertension [93] Company Strategy and Development Direction - The company aims to submit a new drug application (NDA) for lorundrostat, incorporating data from multiple pivotal trials, including the ongoing EXPLORER CKD and EXPLORER OSA trials [8][35] - The appointment of Eric Warren as Chief Commercial Officer is part of the strategy to prepare for potential FDA approval and to enhance commercial efforts [10] - The company is exploring partnerships to maximize the global opportunity for lorundrostat, particularly outside the US [51] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the clinical profile of lorundrostat, highlighting its potential to address significant unmet medical needs in hypertension [6][93] - The company plans to engage with the FDA in a pre-NDA meeting in Q4 2025 to discuss the path forward for lorundrostat [8] - Management emphasized the importance of safety and efficacy data in guiding treatment decisions for patients with advanced chronic kidney disease [30] Other Important Information - The company completed a public equity financing in March 2025, raising approximately $201.2 million, which bolstered its balance sheet [11] - The EXPLORER CKD trial is designed to evaluate lorundrostat's safety and efficacy in patients with chronic kidney disease and hypertension [18] Q&A Session Summary Question: Acceptable level of hyperkalemia in CKD trial - Management indicated that specialists treating advanced kidney disease are more comfortable with higher potassium levels if it leads to improved blood pressure and kidney function [27][30] Question: Efficacy comparison with other treatments - Management anticipates clinically meaningful reductions in blood pressure with lorundrostat, based on previous successful studies [31] Question: Role of EXPLORER CKD in regulatory submission - The EXPLORER CKD study will provide critical data for the NDA submission, particularly for patients with lower eGFR [34][36] Question: Partnering discussions and factors - Management confirmed ongoing discussions with potential partners, emphasizing the need for partners to maximize the opportunity for lorundrostat [60][61] Question: Inclusion of EXPLORER OSA data in NDA - It is too early to determine if data from the EXPLORER OSA trial will be included in the NDA submission [46] Question: Hypertension guidelines and lorundrostat - Management noted that it is uncertain when guidelines will include data from the pivotal trials but emphasized the importance of the data for future treatment paradigms [68] Question: Subgroup analyses in hypertension studies - Management is focused on identifying unique responders to lorundrostat and plans to present subgroup analysis data in the future [75]